{"product_id":"essential-manual-of-24hour-blood-pressure-management-9781119799368","title":"Essential Manual of 24Hour Blood Pressure","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cp\u003eAuthor biography, xi\u003c\/p\u003e \u003cp\u003ePreface – Direction to “Perfect 24-hour Blood Pressure Control”, xv\u003c\/p\u003e \u003cp\u003eAcknowledgments, xix\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Evidence and scientific rationale for ambulatory blood pressure monitoring (ABPM), 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eDiurnal BP variation and the concept of “perfect 24-hour BP control”, 1\u003c\/p\u003e \u003cp\u003eNocturnal hypertension and nocturnal BP dipping status, 3\u003c\/p\u003e \u003cp\u003eNocturnal BP dipping status, 3\u003c\/p\u003e \u003cp\u003eNon-dipper patterns of BP and pulse rate, 3\u003c\/p\u003e \u003cp\u003eRiser pattern of BP and cardiovascular disease risk, 4\u003c\/p\u003e \u003cp\u003eRiser pattern and HF, 7\u003c\/p\u003e \u003cp\u003eRiser pattern and brain damage, 15\u003c\/p\u003e \u003cp\u003eNocturnal hypertension, 17\u003c\/p\u003e \u003cp\u003eAssociated Conditions and Mechanisms of Nocturnal Hypertension, 20\u003c\/p\u003e \u003cp\u003eMechanism of cardiovascular risk of nocturnal hypertension, 22\u003c\/p\u003e \u003cp\u003eExtreme dipping, 24\u003c\/p\u003e \u003cp\u003eMorning surge in BP, 27\u003c\/p\u003e \u003cp\u003eDefinition of MBPS, 33\u003c\/p\u003e \u003cp\u003eMorning BP surge and cardiovascular disease, 34\u003c\/p\u003e \u003cp\u003eMorning BP surge and organ damage, 37\u003c\/p\u003e \u003cp\u003eDeterminants of MBPS, 43\u003c\/p\u003e \u003cp\u003eMechanism of morning risk, 44\u003c\/p\u003e \u003cp\u003eMorning BP surge and hemostatic abnormalities, 46\u003c\/p\u003e \u003cp\u003eVascular mechanism of exaggerated morning BP surge, 49\u003c\/p\u003e \u003cp\u003eBP Variability and systemic hemodynamic atherothrombotic syndrome (SHATS), 52\u003c\/p\u003e \u003cp\u003eThe resonance hypothesis of BP surge, 53\u003c\/p\u003e \u003cp\u003eOrthostatic hypertension, 54\u003c\/p\u003e \u003cp\u003eAmbulatory BP variability, 57\u003c\/p\u003e \u003cp\u003eVisit-to-visit variability in office BP, 58\u003c\/p\u003e \u003cp\u003eVicious cycle between BP variability and vascular disease—SHATS, 59\u003c\/p\u003e \u003cp\u003eWhite-coat and masked hypertension, 71\u003c\/p\u003e \u003cp\u003eWhite-coat hypertension, 73\u003c\/p\u003e \u003cp\u003eMasked hypertension, 75\u003c\/p\u003e \u003cp\u003eAdvances in ABPM, 75\u003c\/p\u003e \u003cp\u003eDevelopment of information and communication technology-based multi-sensor (IMS)-ABPM, 75\u003c\/p\u003e \u003cp\u003eNew ABPM indices, 77\u003c\/p\u003e \u003cp\u003eHI-JAMP registry, 82\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 Scientific rationale for HBPM, 85\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eFive prospective, general practitioner-based, home BP studies, 85\u003c\/p\u003e \u003cp\u003eMorning hypertension, 85\u003c\/p\u003e \u003cp\u003eControl status of morning home BP in the J-HOP study, 88\u003c\/p\u003e \u003cp\u003eEvidence for morning hypertension control, 89\u003c\/p\u003e \u003cp\u003eHome BP variability, 99\u003c\/p\u003e \u003cp\u003eMorning–evening difference (ME-dif), 99\u003c\/p\u003e \u003cp\u003eSD, CV, ARV, and VIM of home BP, 101\u003c\/p\u003e \u003cp\u003eMaximum home SBP, 103\u003c\/p\u003e \u003cp\u003eOrthostatic Home BP Change, 103\u003c\/p\u003e \u003cp\u003eSeasonal variation of home BP and “thermosensitive hypertension”, 109\u003c\/p\u003e \u003cp\u003eAlcohol, 113\u003c\/p\u003e \u003cp\u003eDaytime hypertension (stress hypertension), 115\u003c\/p\u003e \u003cp\u003eNighttime HBPM, 115\u003c\/p\u003e \u003cp\u003eCutting-edge of HBPM, 115\u003c\/p\u003e \u003cp\u003eBasic nighttime home BP monitoring (Medinote), 119\u003c\/p\u003e \u003cp\u003eClinical evidence using nocturnal HBPM: J-HOP nocturnal BP study, 119\u003c\/p\u003e \u003cp\u003eTrigger nighttime BP monitoring, 127\u003c\/p\u003e \u003cp\u003eIT-based trigger nighttime BP monitoring system and the SPREAD study, 133\u003c\/p\u003e \u003cp\u003eCPAP adherence and nighttime BP surge, 135\u003c\/p\u003e \u003cp\u003eAntihypertensive medication on nighttime BP surge, 139\u003c\/p\u003e \u003cp\u003eWrist home HBPM and WISDOM Night study, 145\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Practical use of ABPM and HBPM, 147\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eConcept and positioning of ABPM and HBPM in guidelines, 147\u003c\/p\u003e \u003cp\u003eRecent guidelines, 147\u003c\/p\u003e \u003cp\u003eDiagnosis of masked and white-coat hypertension, 147\u003c\/p\u003e \u003cp\u003eDefinition of morning hypertension, 148\u003c\/p\u003e \u003cp\u003eDefinition of nocturnal hypertension, 150\u003c\/p\u003e \u003cp\u003eWhen to use HBPM and ABPM, 150\u003c\/p\u003e \u003cp\u003eClinically suspected SHATS, 152\u003c\/p\u003e \u003cp\u003eCardio-ankle vascular index (CAVI), 154\u003c\/p\u003e \u003cp\u003eCoupling study, 154\u003c\/p\u003e \u003cp\u003eHow to measure home BP, 155\u003c\/p\u003e \u003cp\u003eNighttime home BP measurement schedule, 159\u003c\/p\u003e \u003cp\u003eABPM parameters, 162\u003c\/p\u003e \u003cp\u003e24-hour BP, 166\u003c\/p\u003e \u003cp\u003eDaytime BP and nighttime BP, 166\u003c\/p\u003e \u003cp\u003eMorning BP parameters, 166\u003c\/p\u003e \u003cp\u003eNighttime BP parameters, 166\u003c\/p\u003e \u003cp\u003eMBPS parameters, 166\u003c\/p\u003e \u003cp\u003eNighttime BP surge parameters, 166\u003c\/p\u003e \u003cp\u003eNighttime BP dipping parameters, 167\u003c\/p\u003e \u003cp\u003eABPM-defined hypertension subtypes, 167\u003c\/p\u003e \u003cp\u003eHome and ambulatory BP-guided management of hypertension, 167\u003c\/p\u003e \u003cp\u003eSTEpwise-Personalized 24-hour BP control approach (STEP24 approach), 167\u003c\/p\u003e \u003cp\u003eTargeting morning hypertension (Step 1), 167\u003c\/p\u003e \u003cp\u003eTargeting nocturnal hypertension (Step 2), 171\u003c\/p\u003e \u003cp\u003ePressor mechanism-based nighttime BP management strategy, 173\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 BP targets, when to initiate antihypertensive therapy, and nonpharmacological treatment, 177\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eClinical implications of antihypertensive treatment, 177\u003c\/p\u003e \u003cp\u003eSPRINT and automated office BP, 177\u003c\/p\u003e \u003cp\u003eMeta-analysis of antihypertensive trials, 177\u003c\/p\u003e \u003cp\u003eWhen to initiate antihypertensive therapy, 178\u003c\/p\u003e \u003cp\u003ePatient preference, 178\u003c\/p\u003e \u003cp\u003eSodium intake, 179\u003c\/p\u003e \u003cp\u003eOther dietary requirements, 181\u003c\/p\u003e \u003cp\u003eExercise, 183\u003c\/p\u003e \u003cp\u003eSleep hygiene, 185\u003c\/p\u003e \u003cp\u003eHousing condition, 185\u003c\/p\u003e \u003cp\u003eApplications and algorithms to facilitate lifestyle modification: CureAPP, 187\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Antihypertensive medication, 189\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eConcept of 24-hour BP lowering including nighttime and morning BPs, 189\u003c\/p\u003e \u003cp\u003eChronotherapy, 189\u003c\/p\u003e \u003cp\u003eAntihypertensive drug choice, 190\u003c\/p\u003e \u003cp\u003eCalcium channel blockers, 190\u003c\/p\u003e \u003cp\u003eAmlodipine, 194\u003c\/p\u003e \u003cp\u003eNifedipine, 195\u003c\/p\u003e \u003cp\u003eCilnidipine, 197\u003c\/p\u003e \u003cp\u003eAzelnidipine, 199\u003c\/p\u003e \u003cp\u003eAngiotensin-converting enzyme inhibitors, 201\u003c\/p\u003e \u003cp\u003eAngiotensin receptor blockers (ARBs), 201\u003c\/p\u003e \u003cp\u003eValsartan, 201\u003c\/p\u003e \u003cp\u003eTelmisartan, 204\u003c\/p\u003e \u003cp\u003eCandesartan, 204\u003c\/p\u003e \u003cp\u003eOlmesartan, 205\u003c\/p\u003e \u003cp\u003eAzilsartan, 206\u003c\/p\u003e \u003cp\u003eDiuretics, 212\u003c\/p\u003e \u003cp\u003eAlpha-adrenergic blockers and beta-adrenergic blockers, 214\u003c\/p\u003e \u003cp\u003eMineralocorticoid receptor blockers (MRB), 215\u003c\/p\u003e \u003cp\u003eAngiotensin receptor-neprilysin inhibitor (ARNi), 217\u003c\/p\u003e \u003cp\u003eEndothelin receptor antagonists (ERA), 221\u003c\/p\u003e \u003cp\u003eCombination therapy, including single pill combinations, 222\u003c\/p\u003e \u003cp\u003eFirst-line therapy, 222\u003c\/p\u003e \u003cp\u003eSecond-line therapy, 222\u003c\/p\u003e \u003cp\u003eClinical trials of antihypertensive combination therapy, 226\u003c\/p\u003e \u003cp\u003eManagement of resistant hypertension, 238\u003c\/p\u003e \u003cp\u003eThird-line therapy, 238\u003c\/p\u003e \u003cp\u003eFourth-line therapy, 239\u003c\/p\u003e \u003cp\u003eSGLT2 inhibitors, 240\u003c\/p\u003e \u003cp\u003eSACRA study, 243\u003c\/p\u003e \u003cp\u003eSHIFT-J study, 244\u003c\/p\u003e \u003cp\u003eLUSCAR study, 248\u003c\/p\u003e \u003cp\u003eSummary, 250\u003c\/p\u003e \u003cp\u003eOther BP-lowering therapies, 252\u003c\/p\u003e \u003cp\u003eHypnotics, 252\u003c\/p\u003e \u003cp\u003eXOR inhibitor, 252\u003c\/p\u003e \u003cp\u003eHerbal medication, 253\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Renal denervation, 255\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eUnsolved issues in the treatment of hypertension and the era for renal denervation, 255\u003c\/p\u003e \u003cp\u003eHypothesis of perfect 24-hour BP control by renal denervation, 256\u003c\/p\u003e \u003cp\u003eHistory, 257\u003c\/p\u003e \u003cp\u003eAdvances in devices, 262\u003c\/p\u003e \u003cp\u003eSymplicity spyral system (radiofrequency thermal ablation), 262\u003c\/p\u003e \u003cp\u003eIberis® system, 264\u003c\/p\u003e \u003cp\u003eParadise system (ultrasonic thermal ablation), 264\u003c\/p\u003e \u003cp\u003ePeregrine system (trans-arterial alcohol injection), 265\u003c\/p\u003e \u003cp\u003eOther energy modalities, 266\u003c\/p\u003e \u003cp\u003eEvidence for renal denervation treatment of hypertension from Sham-controlled trials, 266\u003c\/p\u003e \u003cp\u003eSPYRAL trials, 266\u003c\/p\u003e \u003cp\u003eRadiance-Htn Solo study, 268\u003c\/p\u003e \u003cp\u003eEvidence from Japanese populations, 269\u003c\/p\u003e \u003cp\u003eThe Global Symplicity Registry (GSR), 269\u003c\/p\u003e \u003cp\u003eSafety of the renal denervation procedure, 270\u003c\/p\u003e \u003cp\u003e24-hour BP lowering profile for cardiovascular protection, 270\u003c\/p\u003e \u003cp\u003eResponders and clinical indications, 272\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Blood pressure linked telemedicine and telecare, 278\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eAnticipation medicine, 278\u003c\/p\u003e \u003cp\u003eInnovation technology, 280\u003c\/p\u003e \u003cp\u003eConcept of “trigger” management, 282\u003c\/p\u003e \u003cp\u003eMultisensors and the real-time hybrid Wi-SUN\/Wi-Fi transmission system, 283\u003c\/p\u003e \u003cp\u003eAI and anticipation models, 284\u003c\/p\u003e \u003cp\u003eDevelopment of wearable beat-by-beat (surge) BP monitoring, 285\u003c\/p\u003e \u003cp\u003eSurge index, 292\u003c\/p\u003e \u003cp\u003eDisaster cardiovascular prevention (DCAP) network, 294\u003c\/p\u003e \u003cp\u003eSuccessful anticipation model of ICT-based BP control, 302\u003c\/p\u003e \u003cp\u003eDisaster hypertension, 302\u003c\/p\u003e \u003cp\u003eCOVID-19 era, 305\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Asia perspectives, 311\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eWhat is the HOPE Asia Network?, 311\u003c\/p\u003e \u003cp\u003eHOPE Asia Network achievements, 312\u003c\/p\u003e \u003cp\u003eCharacteristics of cardiovascular disease in Asia, 315\u003c\/p\u003e \u003cp\u003eObesity and salt intake in Asia, 315\u003c\/p\u003e \u003cp\u003e24-hour ambulatory BP profile in Asia, 320\u003c\/p\u003e \u003cp\u003eAsia BP@Home Study, 325\u003c\/p\u003e \u003cp\u003eReferences, 328\u003c\/p\u003e \u003cp\u003eIndex, 368\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e","brand":"John Wiley and Sons Ltd","offers":[{"title":"Default Title","offer_id":49407156519255,"sku":"9781119799368","price":61.7,"currency_code":"GBP","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0817\/1739\/5799\/files\/9781119799368.jpg?v=1730498368","url":"https:\/\/bookcurl.com\/products\/essential-manual-of-24hour-blood-pressure-management-9781119799368","provider":"Book Curl","version":"1.0","type":"link"}